share_log

Vanda Pharmaceuticals Q4 EPS $0.15 Beats $0.14 Estimate, Sales $67.70M Beat $64.00M Estimate

Vanda Pharmaceuticals Q4 EPS $0.15 Beats $0.14 Estimate, Sales $67.70M Beat $64.00M Estimate

萬達製藥第四季度每股收益0.15美元超過預期0.14美元,銷售額6770萬美元超過預期6400萬美元
Benzinga Real-time News ·  2021/02/11 05:01

Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.14 by 7.14 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $67.70 million which beat the analyst consensus estimate of $64.00 million by 5.78 percent. This is a 11.11 percent increase over sales of $60.93 million the same period last year.

萬達製藥(納斯達克:VNDA)公佈的季度收益為每股0.15美元,比分析師普遍預期的0.14美元高出7.14%。這比去年同期每股0.08美元的收益增長了87.5%。該公司公佈的季度銷售額為6770萬美元,比分析師一致預期的6400萬美元高出5.78%。這比去年同期6093萬美元的銷售額增長了11.11%。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論